Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Open Access
- 20 October 2023
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Abstract
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.Keywords
This publication has 33 references indexed in Scilit:
- Silent brain infarct is independently associated with arterial stiffness indicated by cardio-ankle vascular index (CAVI)Hypertension Research, 2012
- Adult Mortality Attributable to Preventable Risk Factors for Non-Communicable Diseases and Injuries in Japan: A Comparative Risk AssessmentPLOS Medicine, 2012
- New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor AliskirenJournal of Pharmacological Sciences, 2010
- Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trialJournal of Human Hypertension, 2009
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 RatsHypertension, 2008
- Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy HumansCirculation, 2008
- Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertensionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, AliskirenHypertension, 2003
- A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimenJournal of Human Hypertension, 2002